Oruka Therapeutics, Inc. (ORKA) News
Follow Oruka Therapeutics, Inc. (ORKA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Oruka Shares Rise More Than 13% After Positive Psoriasis Trial Results
Guggenheim reaffirmed its bullish outlook on Oruka Therapeutics, saying its experimental psoriasis treatment could generate $7 billion in peak sales. Shares were up more than 13% at the time of writing.
EQUITY | Oct 26, 2026, 04:07 PM UTC
M
Oruka Reports Positive Phase 2b Results for Psoriasis Candidate ORKA-001
Oruka Therapeutics reported positive Phase 2b results for its psoriasis candidate ORKA-001.
EQUITY | Oct 26, 2026, 12:13 PM UTC
M
Oruka Reports 61% Complete Skin Clearance at Week 16 in Trial
Oruka Therapeutics said 61% of patients receiving high-dose ORKA-001 achieved complete skin clearance at Week 16 in its Phase 2b psoriasis trial.
EARNINGS | Oct 26, 2026, 12:03 PM UTC
M
Oruka Therapeutics Psoriasis Drug Clears Skin in 61% of Phase 2 Patients
EQUITY | Oct 26, 2026, 11:58 AM UTC
M
Oruka Therapeutics reports positive Phase 2b results for ORKA-001
Oruka Therapeutics reported positive Phase 2b results for its psoriasis drug ORKA-001.
EQUITY | Oct 26, 2026, 11:10 AM UTC
L
Oruka Therapeutics Price Target Maintained With a $165.00/Share by Wedbush
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 12:51 PM UTC
L
Oruka Therapeutics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 11:42 AM UTC
L
Oruka Therapeutics, Inc. (ORKA) Week 28 Psoriasis Data: PASI 100 71.4%
Oruka Therapeutics reported EVERLAST-A Week 28 data for ORKA-001: PASI 100 rose to 71.4% and PASI 90 to 87.3% without dosing after Week 4; safety remained consistent with IL-23 class. Placebo crossovers showed similar re
NEWS | Sep 23, 2026, 11:02 AM UTC
L
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001ORKA-001 maintained a
NEWS | Sep 23, 2026, 11:02 AM UTC
L
ORKA - Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
ORKA - Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
NEWS | Sep 23, 2026, 11:00 AM UTC
L
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) NASDAQ:ORKA, a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of
EQUITY | Sep 09, 2026, 08:03 PM UTC
L
ORKA - Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
ORKA - Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
EQUITY | Sep 09, 2026, 08:01 PM UTC
L
HC Wainwright maintains $120 price target for Oruka Therapeutics
HC Wainwright & Co. maintained its $120.00/share price target on Oruka Therapeutics, according to Benzinga ratings actions.
EQUITY | Sep 03, 2026, 10:27 AM UTC
L
Oruka Therapeutics appoints Todd Edwards as chief commercial officer
Oruka Therapeutics appoints Todd Edwards as chief commercial officer.
MNA | Aug 24, 2026, 08:01 PM UTC
H
Oruka Therapeutics may offer up to $1B of securities
Oruka Therapeutics files with the SEC that it may offer up to $1B of securities, according to Hammerstone MarketTalk.
REGULATION | Aug 21, 2026, 08:20 PM UTC
L
Oruka Therapeutics Insider Sold Shares Worth $846,180, According to a Recent SEC Filing
() -- Arjun Agarwal, Senior Vice President, Finance, on July 13, 2026, sold 9,999 shares in Oruka Therapeutics (ORKA) for $846,180. Following the Form 4 filing with the SEC, Agarwal has control over a total of 15,312 com
GEOPOLITICS | Jul 13, 2026, 09:22 PM UTC
L
Oruka Therapeutics sharers are trading lower after a SEC filing disclosed that Fairmount Healthcare Fund II sold shares worth about $300 mil
Oruka Therapeutics sharers are trading lower after a SEC filing disclosed that Fairmount Healthcare Fund II sold shares worth about $300 million.
REGULATION | Jul 02, 2026, 03:42 PM UTC
L
Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares
Oruka Therapeutics Inc. (NASDAQ: ORKA ) shares fell in after-hours trading on Wednesday after SEC filings showed major shareholder Fairmount Healthcare Fund II sold a large block of shares worth about $300 million. ORKA
REGULATION | Jul 02, 2026, 06:30 AM UTC
L
UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ: ORKA ) with a Buy and raises the price target from $100 to $130.
EQUITY | Jul 01, 2026, 04:13 PM UTC
M
ORKA: HC Wainwright Reiterates Buy
HC Wainwright & Co. reiterates buy rating on Oruka Therapeutics and maintains $120 price target
EQUITY | Jun 23, 2026, 10:52 AM UTC
H
DFTX +65% on Phase 3 Results
DFTX shares rise 65% on positive topline results from Phase 3 Emerge Study of DT120
EQUITY | Jun 22, 2026, 01:17 PM UTC
H
APGE +45% on Acquisition
AbbVie to acquire Apogee Therapeutics, sending APGE stock up 45% premarket
EQUITY | Jun 22, 2026, 12:21 PM UTC